CureVac Touts Positive Preclinical Data for COVID-19 Vaccine
German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response.
The messenger RNA-based vaccine, which is designed to block replication of the coronavirus, was shown to induce neutralizing antibodies and activate T-cells in hamsters and mice.
The data show that the vaccine candidate “has the potential to induce an efficacious and balanced immune response, mimicking the natural immune defense and providing lung protection,” the company said.
The vaccine is currently being evaluated in phase 1 and 2 human clinical trials.